A first-in-human trial of PRT12396 starts next month.
ApexOnco Front Page
Recent articles
Early data are coming with the KRAS G12D degrader ARV-806.
But there are no efficacy data, and the mechanism has a mountain to climb.
CRB-601 and PF-06940434 fall by the wayside.
The company has ditched a trial of drebuxelimab plus ivonescimab.
BPI-572270 enters clinical trials.
A new company will develop “next-generation mRNA” projects, amid another mRNA setback.
Persevera is a bust, but Roche hasn’t given up on the front line.
